Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Industry

Noema's basimglurant gains US orphan status in trigeminal neuralgia, adding to Fast Track

The Swiss biotech's oral mGluR5 drug candidate now holds two FDA regulatory designations for the same pain indication, though no clinical data accompanied the announcement.

16 Nov 2026 · Noema Pharma AG · Company news

Noema Pharma has secured a second US regulatory designation for basimglurant, its investigational therapy for trigeminal neuralgia. The Swiss company said on 16 November 2026 that the FDA had granted the drug orphan status. The compound was previously coded NOE-101.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More IndustryAll →